Abstract
Aim: Thrombopoietin receptor agonists (Tpo increase platelet counts in the majority of chronic autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura; ITP) patients. It is unknown whether this treatment may also improve platelet survival (PS) in these patients. Methods: In order to determine platelet survival (PS), autologous platelets were labeled with 111In oxine and retransfused in six patients under treatment with Tpo RA (romiplostim n = 3; eltrombopag n = 3). Results: Stable platelet counts of greater than 100 × 10 3/μl were observed in all 6 patients. Platelet survival was decreased in all cases (mean 2.10 days; range 0.13-3.73 days). No correlation was found between platelet count and PS. Similarly, there was no significant relationship between platelet turnover and platelet count. However, a high platelet turnover, exceeding 25 or three times the lowest PS (0.13 or 0.83 days). Two patients had a moderately increased platelet turnover rate (63,072 or 72,872 platelets/μl/day). Conclusion: These results indicate that Tpo RA may not only overcompensate platelet destruction in ITP, but may interfere with other mechanisms, which, in some cases, results in a reduced platelet destruction rate. © 2012 S. Karger GmbH, Freiburg.
Author supplied keywords
Cite
CITATION STYLE
Meyer, O., Herzig, E., & Salama, A. (2012). Platelet kinetics in idiopathic thrombocytopenic purpura patients treated with thrombopoietin receptor agonists. Transfusion Medicine and Hemotherapy, 39(1), 5–8. https://doi.org/10.1159/000335553
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.